“Kocitaf” Dolutegravir + Emtricitabine + Tenofovir alafenamide
฿3,200
Kocitaf is a once-daily single-tablet regimen combining dolutegravir, emtricitabine, and tenofovir alafenamide for the effective treatment of HIV-1.
It reduces viral load, maintains long-term suppression, and slows disease progression—all while improving adherence with a simple, convenient regimen. Kocitaf also offers an improved safety profile, with a lower risk of kidney and bone toxicity compared to older treatments.
Kocitaf is a modern, once-daily single-tablet regimen that combines three potent antiretroviral medicines—dolutegravir, emtricitabine, and tenofovir alafenamide. Together, these agents work to effectively suppress HIV-1 replication, making it easier for individuals to achieve and maintain an undetectable viral load.
Dosage and Indication
- Recommended dose: One tablet taken orally once daily, with or without food.
- Should be administered once daily, at the same time each day, to maximize antiretroviral effectiveness and maintain consistent therapeutic levels.
Missed Dose
- If less than 12 hours have passed, take the missed dose as soon as possible and continue your regular schedule.
- If more than 12 hours have passed, skip the missed dose and take the next dose at the usual time.
- Do not take two doses at once.
Therapeutic Benefits
- Achieves and sustains potent viral suppression for effective long-term HIV management
- Simplified once-daily regimen to optimize treatment adherence
- Preserves immunologic function and reduces risk of HIV-related disease progression
- Improved renal and bone safety profile compared to tenofovir disoproxil fumarate–based regimens
